摘要
目的探究硼替佐米联合地塞米松应用于老年多发性骨髓瘤的效果以及对免疫抑制因子、免疫细胞水平的影响。方法随机选取2021年8月—2022年5月济宁市第一人民医院收治的60例多发性骨髓瘤老年患者为研究对象,以随机数表法分为两组,各30例,对照组给予地塞米松、沙利度胺、环磷酰胺联合治疗,观察组采用地塞米松联合硼替佐米治疗,比较两组治疗效果。结果观察组总有效率为93.33%,高于对照组的73.33%,差异有统计学意义(P=0.038)。观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、血清骨钙素(BGP)、血清碱性磷酸酶(ALP)水平高于对照组,CD8^(+)、Ⅰ型胶原C末端肽(CTX-Ⅰ)、白细胞介素-6(IL-6)、白介素-17(IL-17)和乙型转化生长因子(TGF-β)低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为3.33%与对照组的20.00%比较,差异无统计学意义(P>0.05)。结论硼替佐米联合地塞米松应用在老年多发性骨髓瘤老年患者中可改善免疫抑制因子、免疫细胞以及骨代谢因子水平,安全可靠。
Objective To explore the effect of bortezomib combined with dexamethasone in the treatment of elderly multiple myeloma and its influence on the levels of immunosuppressive factors and immune cells.Methods 60 elderly patients with multiple myeloma admitted to the First People′s Hospital of Jining City from August 2021 to May 2022 were randomly selected as the study objects,and were divided into two groups with 30 cases each by random number table method.The control group was given combined treatment with dexamethasone,thalidomide and cyclophosphamide,and the observation group was given combined treatment with dexamethasone and bortezomib,and the therapeutic effects of the two groups were compared.Results The total effective rate of the observation group was 93.33%,higher than that of the control group(73.33%),and the difference was statistically significant(P=0.038).The levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),serum osteocalcin(BGP)and serum alkaline phosphatase(ALP)in the observation group were higher than those in the control group.CD8^(+),C-terminal peptide of type I collagen(CTX-Ⅰ),interleukin-6(IL-6),interleukin-17(IL-17)and transforming growth factor B(TGF-β)were lower than those of control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 3.33%compared with 20.00%in the control group,and the difference was not statistically significant(P>0.05).Conclusion Bortezomib combined with dexamethasone can improve the levels of immunosuppressive factors,immune cells and bone metabolic factors in elderly patients with multiple myeloma,which is safe and reliable.
作者
肖萌
XIAO Meng(Department of Hematology,Jining First People′s Hospital,Jining,Shandong Province,272001 China)
出处
《中外医疗》
2023年第18期35-39,共5页
China & Foreign Medical Treatment
基金
济宁市科学技术局科研项目(2021YXNS010)。
